麻豆传媒

USPSTF screening recommendations, broader indication for ribociclib, OS win for pembrolizumab

ProSense device would be indicated with adjuvant endocrine therapy for some low-risk patients

Largest survival benefit observed in patients who entered a cessation program within 6 months

Large cohort study showed cancer risk increased with exposure to fine particulate matter

Study also showed that patients were more likely to receive timely treatment

Absolute risk remains low, however

Trials now enroll lower-risk women who get better treatment, analysis suggests

Adding inavolisib to palbociclib/fulvestrant more than doubled PFS in endocrine-resistant disease

Bladder, brain, and cervical cancer risks were higher in people with MS

Health news and commentary gathered by 麻豆传媒 staff

Higher risk for ever use, increasing duration of use but no increase in BRCA2 carriers

Health news and commentary gathered by 麻豆传媒 staff

Trial finds similar complication and recurrence rates with hypofractionated versus standard RT

Numerical advantage in randomized trial, non-randomized study misses noninferiority mark